Tier A · Established human benefit
Tirzepatide
A dual-incretin peptide with major human benefits across weight and metabolic health.
Why researchers care
Potential human relevance
- Large average weight reductions in chronic weight-management trials
- Strong glucose-lowering effects in type 2 diabetes
- FDA-approved for chronic weight management
- FDA-approved for moderate-to-severe obstructive sleep apnea in adults with obesity
What the human evidence says
Evidence, not extrapolation
Tirzepatide has extensive randomized clinical trial evidence and established approved uses. Its dual GIP/GLP-1 mechanism helped redefine what peptide-based metabolic therapy can achieve.
How to think about it
The Yooper Peptides take
The most interesting science is not just appetite suppression. Tirzepatide shows how combining peptide signaling pathways can produce broader metabolic effects.
Primary / authoritative reading